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Mechanisms of induction of renal allograft tolerance in CD45RB- tion [1]. The current goal of transplant immunology is
treated mice. to develop better immunotherapeutic protocols that are
Background. Rejection is the most significant problem in aimed at specifically suppressing alloreactivity. The ma-the field of transplantation. The current goal of transplant
jor objection to the currently available immunosuppres-immunology is to develop better immunotherapeutic protocols
sion is the nonspecific depression that these therapiesthat are aimed at specifically suppressing alloreactivity and
preserving an otherwise intact immune system. We have pre- produce, which affects nearly all of the immunological
viously shown that mice will accept renal allografts indefinitely and inflammatory responses. Because cell-mediated im-
with normal renal function after two injections of a monoclonal
munity is an important mechanism of rejection, it is rea-antibody to the CD45RB protein. Furthermore, this antibody
sonable to aim therapy primarily against this arm of thewill reverse acute rejection when therapy is delayed until day
4 and will still induce tolerance. The mechanisms of this thera- immune system [2]. The use of antibodies represents
peutic benefit are not known. one approach to this goal. A variety of polyclonal and
Methods. BALB/C mice were used as recipients of major monoclonal antibodies (mAb) have been used with vari-multiple histocompatibility complex-mismatched kidneys using
ous degrees of success, and these preparations have im-C57BL/6 as donors. Immunoperoxidase microscopy and North-
portant side effects [3–21]. Thus, our objective was toern blots for cytokine gene expression were used to study
the renal allografts. Fluorescence-activated cell sorter (FACS) induce a prolonged state of nonreactivity to the trans-
analyses of peripheral blood lymphocytes were performed. plant while preserving an otherwise intact immune sys-
Phosphotyrosine peptide phosphatase assays were performed
tem, as currently the therapy available remains unsatis-on splenic lymphocyte membranes.
factory and inadequate.Results. A CD45RB monoclonal antibody (MB23G2) in-
duced tolerance and partially depletes peripheral blood lym- To identify new lymphocyte surface proteins that may
phocytes. A therapeutically ineffective CD45RB monoclonal be targeted to more specifically prevent alloreactivity,
antibody (MB4B4) merely coated the circulating lymphocytes. we reviewed the binding properties of polyclonal anti-Furthermore, MB23G2 stimulated more tyrosine phosphatase
lymphocyte globulin. Although there are measurableactivity than MB4B4 in mouse T-cell membranes.
quantities of antibodies binding to a variety of cell sur-Conclusions. The clearance of peripheral blood lymphocyte
populations and stimulation of protein tyrosine phosphatase face proteins, the greatest reactivity is to a series of high
activity may be important in the mechanism of tolerance induc- molecular weight glycoproteins termed the leukocytetion by CD45RB therapy, which may be clinically relevant in
common antigen by Fabre and Williams, and now knownthe therapy of organ rejection in humans.
as CD45 [22–26]. Earlier, we have shown that a mAb
directed against the RB isoform of CD45 induces a sub-
stantial inhibition of alloreactivity of human CD41 lym-The single largest impediment to success in the field
phocytes in vitro [27]. CD45RB is present on all peripheralof transplantation continues to be the problem of rejec-
blood lymphocytes and monocytes and is substantially
down-regulated with activation on T cells [28]. In lym-Key words: transplantation, organ rejection, renal alloreactivity, pe-
ripheral blood lymphocytes, protein tyrosine phosphatase. phoid tissues, it is differentially expressed on T- and
B-cell subpopulations [29].Received for publication July 10, 1997
We have reported that CD45RB is an appropriate tar-and in revised form August 27, 1998
Accepted for publication November 10, 1998 get for the prevention and reversal of renal allograft rejec-
tion in mice [30]. Two injections of 30 mg of a CD45RB 1999 by the International Society of Nephrology
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mAb induced indefinite renal allograft acceptance and (ATCC), and MHC Class II (Ia; Serotec). Slides were
evaluated in a masked maneuver as described [32].subsequent tolerance to skin transplants. Furthermore,
To examine gene expression in the allografts, steady-CD45RB mAb could reverse an acute rejection crisis
state levels of specific mRNA transcripts were assessedand still lead to tolerance. The mechanisms of this thera-
by Northern blot using specific 32P-labeled cDNA probespeutic benefit are not known. In this study, we demon-
and semiquantitative polymerase chain reaction as pre-strate that a CD45RB mAb that is able to induce toler-
viously described [33]. Scanning densitometry analysisance partially depletes peripheral blood lymphocytes,
of autoradiographs of b-actin was used to establish equalwhereas a therapeutically ineffective CD45RB mAb does
loading of RNA and to allow comparisons between treat-not. We also provide evidence that a CD45RB mAb that
ment groups.induces tolerance stimulates more tyrosine phosphatase
activity than does an ineffective CD45RB mAb.
Pharmacologic effects of MB23G2 and MB4B4 on the
phenotype of peripheral blood lymphocytes
METHODS The administration of certain mAbs to patients such
as OKT3 has a variety of well-documented effects onSurgical model
the phenotype of circulating peripheral blood lympho-Male inbred mice strains, C57BL/6 (H-2b) and BALB/
cytes [5]. One of the most reliable ways of evaluatingc (H-2d), were supplied by Harlan Sprague-Dawley (Indi-
the effectiveness of OKT3 therapy has been the measure-anapolis, IN, USA), and were housed under conven-
ment of the numbers of circulating CD31 T cells. Wetional conditions at our animal care facility (University
therefore designed experiments to evaluate the effects ofof Western Ontario, London, Ontario, Canada). Mice
MB23G2 and MB4B4 on circulating lymphocytes. Fourweighing between 25 and 30 g were used for all experi-
groups of mice were treated with 30 mg of MB23G2 orments. Kidney transplants were performed across major
MB4B4 mAbs intravenously on seven consecutive days.multiple histocompatibility complex (MHC) mismatches
The animals were sacrificed before therapy on day 0using C57BL/6 as the donor and BALB/c as the recipient.
(N 5 6), day 3 (N 5 6), day 7 (N 5 6), and day 14A two-stage procedure was performed in which the re-
(N 5 5). The heparinized blood was analyzed on eachcipient’s left native kidney was left in place while the
animal for a white blood cell count and differential. Theright native kidney was removed at the time of trans-
mean (6 sem) absolute lymphocyte count was then calcu-plantation [31]. The left native kidney was then removed
lated. The buffy coat was also analyzed by fluorescence-
on the seventh postoperative day. The animals were ob-
activated cell sorter (FACS) analysis using standard tech-
served daily until death. The results of the transplant niques and equipment as described previously [15, 27].
experiments have been reported [30]. There were four We also determined whether the administered CD45RB
groups of animals. One group received isografts that antibodies cleared circulating lymphocytes or whether
survived indefinitely. The second group received allo- the cells continued to circulate while coated with the
grafts with no immunosuppression, and most promptly CD45RB antibodies. Goat antirat fluorescein isothiocya-
rejected their kidneys within 10 days. The third group nate only bound strongly to those cells that were ren-
received two doses of rat antimouse CD45RB mAb dered rat Ig positive by the administered therapy. Phy-
MB23G2 (ATCC) [28] 1 mg/kg (30 mg) intravenously coerythrin-conjugated CD3 mAb was used to identify
on days 0 and 1. This group’s survival was statistically the T cells, and for analysis of positivity both the percent-
the same as the isograft group. A fourth group received age positive and absolute number were determined by
two doses of rat antimouse CD45RB mAb MB4B4 gating on the CD31 T cells. In a separate tube, phycoer-
(ATCC) [28] 1 mg/kg (30 mg) intravenously on days 0 ythrin-conjugated goat antimouse Ig was used to identify
and 1. This group’s survival was statistically the same as the B cells. Again, gating was used to identify the coated
the untreated allograft group. B cells. Negative fluorescence was based on markers set
around irrelevant control antibodies; however, the best
Immunohistology and cytokine expression within control was the staining of the untreated animal’s periph-
kidney transplants eral blood lymphocytes. Any increase in goat antirat
Immunoperoxidase microscopic studies were performed fluorescein isothiocyanate staining of the gated cells must
on the renal allografts at 7 days in three groups of mice be because of coating of the CD45RB antigen by admin-
(untreated, MB4B4 treated, and MB23G2 treated). The istered MB23G2 or MB4B4 therapy.
frozen sections were stained using an avidin-biotin per-
Effects of MB23G2 and MB4B4 on tyrosineoxidase technique [29]. Monoclonal antibodies used for
phosphatase activityphenotypic analysis were CD3 mAb KT3 (Serotec, To-
ronto, Ontario, Canada), CD4 mAb L3T4 (GK1.5, ATCC), Tyrosine phosphatase activity of immunoprecipitated
CD45RB was assayed using the protocol of Ng et al [34].CD8 mAb Lyt2 (3.155, ATCC), CD45RB mAb MB23G2
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Briefly Triton X-100 lysates of 3 3 107 total spleen cells or
BW5147 cells (CD45 negative) was immunoprecipitated
with MB4B4, MB23G2, or IgG-conjugated agarose beads
at 48C for one hour. The beads were spun down and washed
twice in the lysis buffer and three times in nonreducing
tyrosine phosphatase buffer [50 mm imidazole Cl, pH
7.2, 1 mm ethylenediaminetetraacetic acid (EDTA)] and
resuspended in 200 ml of this buffer with 0.1% 2-mercap-
toethanol. Ten microliters of beads were incubated with
5 mm tyrosine phosphorylated src peptide substrate in 30
ml total volume. The reaction was stopped by the addition
of 80 ml of color reagent (one part 0.135% malachite
green oxalate, one part 4.2% ammonium molybdate, two
parts H2O, in 0.01% Tween 20). The color reaction was
allowed to proceed for 30 minutes, and then absorbance
at 650 nm was measured.
Tyrosine phosphatase activity on the total membrane
preparations was determined as mentioned earlier, ex-
cept that purified membranes from equivalent cell num-
bers were used instead of immunoprecipitated CD45RB.
In experiments in which membrane preparations were
used, 10 mg of MB4B4, MB23G2, or IgG were added to
the assay to stimulate tyrosine phosphatase activity.
RESULTS
Fluorescence-activated cell sorter analysis of
peripheral blood lymphocytes
Certain mAbs seem to exert their immunotherapeutic
benefit in part by depleting peripheral blood lympho-
cytes [5, 8], whereas other mAbs do not have the ability
to deplete and may be less therapeutically efficacious
[15]. That being said, nondepleting CD4 and CD8 mAbs
are highly effective and have been reported to induce
“infectious tolerance” [35]. Thus, an ability to deplete
peripheral blood lymphocytes may be an indication of
efficacy, but not in all cases. We therefore wished to
assess whether there was a difference in the pharmaco-
logical effect of the tolerance-inducing MB23G2 mAb
compared with the ineffective MB4B4 mAb. As can be
seen in Figure 1A, MB23G2 induced a substantial and
Fig. 1. CD45RB monoclonal antibody (mAb) MB23G2 induces toler-statistically significant decrease in the number of circulat- ance and partially depletes peripheral blood lymphocytes, whereas the
ing peripheral blood lymphocytes, as we have shown CD45RB mAb MB4B4 has no efficacy and coats peripheral blood
lymphocytes. (A) Four groups of mice were treated daily with MB23G2previously [30]. Remarkably, the therapeutically ineffec-
mAb (X) or MB4B4 mAb (d) for up to seven consecutive days. Thetive mAb MB4B4 had no effect on the number of circu- animals were sacrificed before therapy on day 0, 3, 7, and 14. Blood was
lating peripheral blood lymphocytes, despite seven days analyzed from each animal for a white blood cell count and differential
analysis. The mean (6 sem) absolute lymphocyte count was then calcu-of MB4B4 therapy at a dose of 100 mg per day intrave-
lated. The difference between day 0 and day 14 is not significant in thenously. Figure 1 B and C demonstrate that MB4B4 MB23G2 group, and none of the days are significantly different in the
bound to most of the circulating T cells and B cells, as MB4B4 group. The difference between days 0/14 and days 3/7 in the
MB23G2 group is significant (P 5 0.05 Wilcoxon rank sum test). (Bmeasured by multiparameter FACS analysis. MB4B4
and C) Four groups of mice were treated with MB4B4 mAb as in (A).saturated all CD45RB sites during therapy, as no further Their blood samples were collected at four time points, and prepared
MB4B4 could be added to the cells. During this time, for FACS analysis, as described in the Methods section. Goat antirat
fluorescein isothiocyanate was used to detect bound MB4B4. Anti-there was excess MB4B4 and MB23G2 mAb in the
CD3PE was used to identify T cells (B), and goat antimouse PE wasplasma. This assay was performed by adding 50 ml of used to detect B cells (C). The absolute number of positive cells (d)
plasma from the treated animals to normal spleen cells was calculated from the percentage positive (X) on each cell type.
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Fig. 2. Immunopathology of renal allografts. Light micrographs were obtained from three groups of animals (N 5 5). Untreated kidney transplant
(first column), MB4B4-treated kidney transplant (second column), and MB23G2-treated kidney transplant (third column) were taken all on day 7.
Monoclonal antibodies were used for the phenotypical analysis of frozen tissue sections revealed by an avidin-biotin peroxidase technique [29].
Row 1, CD3 mAb KT3; row 2, CD4 mAb L3T4; row 3, CD8 mAb Lyt2; row 4, CD45RB mAb MB23G2; row 5, MHC Class II, Ia. Publication
of this figure in color was made possible by a grant from Research Corporation Technologies, Tucson, AZ, USA.
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Fig. 3. Tumor necrosis factor a, g interferon,
and intercellular adhesion molecule 1 expression
are down-regulated by MB23G2 (CD45RB)
mAb therapy in mouse renal allografts by day
28. Gene expression was detected by Northern
analysis. The blots were probed for tumor ne-
crosis factor a (A), g interferon (B), and inter-
cellular adhesion molecule 1 (C). Lanes 1 to 5
are five untreated renal isografts assessed on
postoperative day 7. Lanes 6 to 10 are five un-
treated renal allografts assessed on postopera-
tive day 7. Lanes 11 to 15 are five MB23G2-
treated renal allografts assessed on postopera-
tive day 28. There was no difference between
MB23G2-treated renal allografts analyzed on
day 7 and untreated allografts (data not shown).
Gene expression is down-regulated by day 28.
The renal isograft in (A), lane 1, expressed tu-
mor necrosis factor g. This organ was affected
by pyelonephritis as a complication.
from another Balb/C mouse and revealing binding using CD45RB, and Ia. The aggregates and diffuse infiltrates
were evaluated as described [32]. There were high num-a fluorescein-conjugated antirat Ig [15]. FACS analysis
of the spleen also revealed that the administered mAb bers of CD41 and CD81 cells in all three groups in the
aggregates. The diffuse infiltrates demonstrated substan-penetrated the lymphoid tissue. A FACS inhibition assay
[15] revealed no evidence of sensitization to either mAb tially fewer CD31 and CD81 cells in the MB23G2-
treated kidneys compared with MB4B4 and untreatedtwo weeks after therapy. Thus, a most striking difference
between the two mAbs was that the effective MB23G2 kidneys. Staining for Ia was substantial in all three
groups, but there were no differences in CD41 andwas a partially depleting antibody, whereas the therapeu-
tically ineffective MB4B4 was a nondepleting antibody. CD45RB1 cells in the three groups. Thus, the MB23G2-
treated animals demonstrated an elevated CD4:CD8 ra-
Immunohistology tio compared with the MB4B4 and untreated animals.
Surprisingly, very few of the infiltrating cells wereImmunoperoxidase microscopic studies were performed
on renal allografts at seven days in three groups of mice CD45RB positive (Fig. 2; fourth row). Despite the pau-
city, MB23G2 was able to reverse acute rejection and(untreated, MB4B4 treated, and MB23G2 treated). As
shown in Figure 2, sections were stained with rat anti- lead to indefinite allograft survival when therapy was
delayed to day 4 [30].mouse mAb that was reactive with CD3, CD4, CD8,
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Cytokine expression in renal transplants
Although the role of T helper (TH) subsets in allograft
rejection is not completely understood, an association
with TH1 lymphocytes expressing interleukin (IL)-2 and
g interferon has been described in several organ models
[36]. Consistent with this concept, a shift to a TH2 subset
expressing IL-4, IL-5, and IL-10 may prevent graft injury
by infiltrating cells. The MB23G2-treated allografts had
interstitial infiltrates of mononuclear cells, but there was
no evidence of tissue damage. To examine gene expres-
sion in the allografts, steady-state levels of specific
mRNA transcripts were assessed by Northern blot using
specific 32P-labeled cDNA probes. We studied four groups
of animals: isografts on postoperative day 7, untreated
allografts on postoperative day 7, and MB23G2-treated
animals on postoperative days 7 and 28. MB23G2-treated
animals had reduced levels of steady-state mRNA tran-
scripts for g interferon and tumor necrosis factor a on
day 28 compared with untreated allografts on day 7 (Fig.
3), but no differences were noted between treated and
untreated mice on day 7. Thus, the decrease in cytokine
gene expression in the MB23G2 group may be a result of
tolerance at day 28 rather than a specific pharmacologic
effect of the mAb. Consistent with a reduction in g inter-
feron, intercellular adhesion molecule-1 mRNA was also
decreased in the MB23G2-treated animals on day 28
(Fig. 3), but there was no difference on day 7. Fig. 4. (A) Immunoprecipitation of active CD45RB from spleen cell
lysates. CD45RB was immunoprecipitated with MB4B4, MB23G2, or
Effects of CD45RB monoclonal antibodies on tyrosine IgG conjugated agarose from Triton X-100 lysates of 3 3 107 total
spleen cells. Immunoprecipitates were assayed for liberation of inor-phosphatase activity
ganic phosphate from a phosphorylated src substrate, using the mala-
As CD45 is the crucial protein tyrosine phosphatase chite green-oxalate assay and measuring absorbance at 650 nm. (B)
Immunoprecipitation was performed on lysates from BW5147 cells thatin T-lymphocyte signal transduction through the protein
lack CD45 expression. Immunoprecipitates were assayed for liberationtyrosine kinases p56lck and p59fyn, we wished to determine of inorganic phosphate from a phosphorylated src substrate, using the
whether the CD45RB mAbs had a biochemical effect on malachite green-oxalate assay and measuring absorbance at 650 nm.
the tyrosine phosphatase activity of splenic lymphocytes.
As shown in Figure 4A, both MB23G2 and MB4B4 mAbs
immunoprecipitated substantial but equal amounts of ty-
may be considered. CD45RB mAb may interfere withrosine phosphatase activity from splenic lymphocytes.
T-cell signal transduction perhaps by steric hindrance,BW5147 cells were CD45 negative, and consequently,
thereby preventing interaction of the extracellular do-neither MB23G2 nor MB4B4 could immunoprecipitate
main of the CD45RB protein with its natural ligand. Thetyrosine phosphatase activity from these cells’ mem-
stimulation by effective CD45RB mAb MB23G2 has abranes (Fig. 4B). However, as shown in Figure 5,
substantial effect on tyrosine phosphatase activity, whichMB23G2 stimulated a substantial amount of tyrosine
may result in a critical alteration of activation of thephosphatase activity on the splenic lymphocyte mem-
protein tyrosine kinases p56lck and p59fyn [37]. Signalbranes, whereas MB4B4 was only slightly above back-
transduction may also be affected because of improperground. Thus, the tolerance-inducing mAb MB23G2 has
aggregation of multiple components of the T-cell recep-an important effect on tyrosine phosphatase activity,
tor, including CD7 and the CD3 polypeptides. Both CD3whereas the therapeutically ineffective mAb MB4B4 has
and CD7 are immunosuppressive targets [5, 15], and weless ability to induce tyrosine phosphatase activity.
have shown that CD3, CD7, and CD45 form an oligo-
meric complex on human T cells [38].
DISCUSSION The CD45RB mAb MB23G2 is a depleting antibody,
that is, it does not merely coat circulating peripheralCD45RB-directed therapy is a novel mode of immu-
nosuppression for allograft rejection. The mechanisms of blood lymphocytes, but it substantially removes them
from the circulation. OKT3 has the same property andtolerance induction are unclear, but several possibilities
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transduction related to augmented tyrosine phosphatase
activity compared with MB4B4 stimulation. Whatever
the reason for the differences between the antibodies, it
is notable that the CD45RB protein is limited to a subset
of leukocytes in the allograft, yet CD45RB mAb
MB23G2 has the ability to reverse a rejection crisis. Our
data indicate that CD45RB is an important molecule in
transplant rejection and may find clinical application in
organ transplantation in humans.
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